United States : ZOSANO PHARMA'S ZP-Glucagon Patch Phase 2 Study obtains Better outcomes.
Zosano Pharma Corporation, a clinical-stage specialty pharmaceutical firm, declared positive outcomes from the Phase 2 clinical trial of its proprietary, quick onset, transdermal ZP-Glucagon patch for severe hypoglycemia.
The goal of the Phase 2 clinical program was to assist the safety and efficacy of the ZP-Glucagon patch in comparison to the standard-of-care in reversing insulin ingested hypoglycemia in adult subjects with Type 1 diabetes.
2 doses of the ZP-Glucagon patch were in comparison with 2 doses of intramuscular injections in an open-label, randomized, 4-way crossover study design.
The 2 ZP-Glucagon patch doses eases blood sugar in 100% of the patients.
Both patch doses had quick onset of action and time to glucose response was alike among the 2 modes of administration.
Each cure were well tolerated and no new protection issues were recognized.
Thorsten von Stein, Chief Medical Officer said, "Achieving positive results from this Phase 2 study with the Zosano ZP-Glucagon patch is another significant milestone for the company. ZP-Glucagon s dry, stable formulation and simple press-and-apply application represents a significant improvement over the currently marketed products for treatment of severe hypoglycemia, which often require a lay person to deliver an injection with a cumbersome preparation and reconstitution process.
[c] 2015 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Oct 16, 2015|
|Previous Article:||United States : NEW textile colour management tool launched by X-Rite.|
|Next Article:||United States : AVIATION FIRM seeking to recruit 50 airplane mechanics locally.|